[go: up one dir, main page]

DK0528767T3 - antistofderivater - Google Patents

antistofderivater

Info

Publication number
DK0528767T3
DK0528767T3 DK92810633T DK92810633T DK0528767T3 DK 0528767 T3 DK0528767 T3 DK 0528767T3 DK 92810633 T DK92810633 T DK 92810633T DK 92810633 T DK92810633 T DK 92810633T DK 0528767 T3 DK0528767 T3 DK 0528767T3
Authority
DK
Denmark
Prior art keywords
antibody derivatives
cancer
hiv
infections
aids
Prior art date
Application number
DK92810633T
Other languages
English (en)
Inventor
Hans Loibner
Mau Sung Co
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919118013A external-priority patent/GB9118013D0/en
Priority claimed from GB929204514A external-priority patent/GB9204514D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0528767T3 publication Critical patent/DK0528767T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK92810633T 1991-08-21 1992-08-18 antistofderivater DK0528767T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919118013A GB9118013D0 (en) 1991-08-21 1991-08-21 Monoclonal antibodies and their use
GB929204514A GB9204514D0 (en) 1992-03-02 1992-03-02 Monoclonal antibodies and their use

Publications (1)

Publication Number Publication Date
DK0528767T3 true DK0528767T3 (da) 2000-04-17

Family

ID=26299429

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92810633T DK0528767T3 (da) 1991-08-21 1992-08-18 antistofderivater

Country Status (10)

Country Link
US (1) US5562903A (da)
EP (1) EP0528767B1 (da)
JP (1) JP3474592B2 (da)
AT (1) ATE188708T1 (da)
CA (1) CA2076432C (da)
DE (1) DE69230545T2 (da)
DK (1) DK0528767T3 (da)
ES (1) ES2145004T3 (da)
GR (1) GR3032944T3 (da)
PT (1) PT528767E (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69324584T2 (de) * 1992-05-22 1999-09-23 Novartis Ag, Basel Antiidiotypische monoklonale antikörper gegen den lewis y-spezifischen monoklonalen antikörper br55-2 und deren verwendungen
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
EP0781847A1 (en) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanized monoclonal antibody
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
HUP0301208A2 (hu) * 1999-02-12 2003-08-28 Genetics Institute, Llc B7-molekulákkal reagáló humanizált immunglobulin és az ezekkel végzett kezelési eljárások
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
AT500648B1 (de) 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
US7780992B2 (en) * 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
WO2006005367A1 (en) * 2004-07-14 2006-01-19 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
AU2006210724A1 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
KR101416078B1 (ko) 2006-05-25 2014-07-07 글락소 그룹 리미티드 변형된 인간화 항­인터루킨­１８ 항체
EP2044120B1 (en) * 2006-06-07 2019-01-30 BioAlliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US7741446B2 (en) * 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
EP2716657A3 (en) * 2006-12-20 2014-10-08 Mmrglobal, Inc. Antibodies and methods for making and using them
EP2182980A4 (en) 2007-07-27 2012-04-18 Armagen Technologies Inc METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
NZ585959A (en) 2007-12-18 2012-09-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
SG186689A1 (en) * 2007-12-28 2013-01-30 Univ Tennessee Res Foundation Treatment and prophylaxis of amyloidosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8859205B2 (en) * 2009-01-08 2014-10-14 Bio-Rad Laboratories, Inc. Methods and compositions for improving efficiency of nucleic acids amplification reactions
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP3533467B1 (en) 2009-10-09 2023-07-26 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
EP2569013B1 (en) * 2010-05-14 2016-11-23 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
JP2012067106A (ja) * 2011-10-14 2012-04-05 Greenovation Biotech Gmbh グリコシル化抗体
JP6266529B2 (ja) 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおけるアリールスルファターゼａ活性を増加するための方法および組成物
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
CN109266656B (zh) * 2018-10-10 2021-02-19 江苏集萃药康生物科技股份有限公司 一种PD1人源化BALB/c小鼠模型的构建方法及其应用
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0256654B1 (en) * 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen

Also Published As

Publication number Publication date
ATE188708T1 (de) 2000-01-15
JPH05336989A (ja) 1993-12-21
GR3032944T3 (en) 2000-07-31
CA2076432C (en) 2003-10-21
US5562903A (en) 1996-10-08
PT528767E (pt) 2000-06-30
EP0528767B1 (en) 2000-01-12
DE69230545D1 (de) 2000-02-17
EP0528767A1 (en) 1993-02-24
JP3474592B2 (ja) 2003-12-08
ES2145004T3 (es) 2000-07-01
DE69230545T2 (de) 2000-07-06
CA2076432A1 (en) 1993-02-22

Similar Documents

Publication Publication Date Title
DK0528767T3 (da) antistofderivater
ATE123652T1 (de) Antigene.
IT9068053A0 (it) Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
DE3783277D1 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
DK0552296T3 (da) Monoklonale antistoffer fra mus
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
EP0198086A4 (en) MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY.
NO870476L (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
DE3485712D1 (de) Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.
FI885169L (fi) Monoklonaalinen vasta-aine, joka tunnistaa N-asetyylineuramiinihapon -järjestyksessä, sen käyttö ja sitä tuottava hybridooma
ATE137674T1 (de) Von mca 16-88 erkanntes antigen
DE69119591D1 (de) Das von mca-28a32 erkannte antigen
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
NO944443L (no) Monoklonale antistoffer
DE69025629D1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids-verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
EP0334076A3 (en) Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
DE3882066D1 (de) Monoclonaler antikoerper gegen menschliches lungenadenokarzinom.
NO952506L (no) Antistoffpreparater mot homogent minaktivin og anvendelse derav for påvisning av minaktivin i humane kroppsvæsker
FI883765L (fi) Antikroppar mot biologiskt aktiva polypeptider och deras anvaendning vid diagnostiska foerfaranden.